Mona Malik, Ph.D. is a co-author of this article which focuses on topoisomerase II, a target for clinically active anticancer drugs. Drugs targeting these enzymes act by preventing the religation of enzyme-DNA covalent complexes leading to protein-DNA adducts that include single- and double-strand breaks. In mammalian cells, nonhomologous repair pathways are critical for repairing topoisomerase II-mediated DNA damage.
Mona Malik, Ph.D., supports patent prosecution and litigation and provides technical and scientific guidance in various fields of life sciences, including cell biology, immunology/immunotherapy, genetics, biochemistry, pharmacology, virology, oncology, plant sciences and agriculture. With an advance degree and more than a dozen years of research experience, Mona brings noteworthy credentials to the patent issues of intellectual property. She earned a Ph.D. from the University of Cambridge after investigating complex mechanisms of chromosomal gene recombination and gene replacement.To access the full article, please visit American Association for Cancer Research.